Trends in National Pharmaceutical Expenditure in Korea during 2011 - 2020
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: This study aimed to identify the trends in pharmaceutical expenditure (PE), share of PE in health expenditure (HE), and trends in expenditure by pharmacological groups (ATC level 1 classification) in Korea for a 10-year period (2011 - 2020) and compare the data with those of other Organisation for Economic Co-operation and Development (OECD) countries. Using the findings, we determined the current status of pharmaceutical expenditure (PE) management in Korea and derived the implications for establishing future macroscopic policies on PE. Materials and Methods: We analyzed the OECD Health Statistics and the Korean national health insurance claims database from January 2011 through December 2020. The outcome measures were HE, PE, and pharmaceutical sales data for ATC level 1 medicines from OECD Health Statistics data during 2011 - 2020. As OECD collects limited ATC level 1 data, we used the HIRA health insurance claims data for PEs of ATC level-1 classification, including D, L, P, and S. Results: PE in Korea increased by 38.5% from 19.9 billion USD in 2011 to 27.6 billion USD in 2020, whereas the share of PE in HE decreased by 6.3%p from 26.4% in 2011 to 20.1% in 2020. In 2020, Korea ranked third in PE per capita (760.9 USD PPP) and had the highest share of PE (20.1%) among the 19 OECD countries studied. By ATC level 1 class, the highest PE was A (alimentary tract and metabolism) at 4.3 billion USD, and L (antineoplastic and immunomodulating agents) had the highest increase at 13.4%; in contrast, J (anti-infectives for systemic use) had the lowest increase in annual average PE at −0.2% in 2020 relative to 2011. Among the 17 OECD countries, Korea had the highest and the third-highest expenditures for ATC codes A and J, respectively. Conclusion: PE in Korea has continued to increase between 2011 and 2020, indicating the need for macroscopic management of PE. Our results on PE by ATC code may help health authorities in establishing future policies on PE.
Abstract
Background: This study aimed to identify the trends in pharmaceutical expenditure (PE), share of PE in health expenditure (HE), and trends in expenditure by pharmacological groups (ATC level 1 classification) in Korea for a 10-year period (2011 - 2020) and compare the data with those of other Organisation for Economic Co-operation and Development (OECD) countries. Using the findings, we determined the current status of pharmaceutical expenditure (PE) management in Korea and derived the implications for establishing future macroscopic policies on PE. Materials and Methods: We analyzed the OECD Health Statistics and the Korean national health insurance claims database from January 2011 through December 2020. The outcome measures were HE, PE, and pharmaceutical sales data for ATC level 1 medicines from OECD Health Statistics data during 2011 - 2020. As OECD collects limited ATC level 1 data, we used the HIRA health insurance claims data for PEs of ATC level-1 classification, including D, L, P, and S. Results: PE in Korea increased by 38.5% from 19.9 billion USD in 2011 to 27.6 billion USD in 2020, whereas the share of PE in HE decreased by 6.3%p from 26.4% in 2011 to 20.1% in 2020. In 2020, Korea ranked third in PE per capita (760.9 USD PPP) and had the highest share of PE (20.1%) among the 19 OECD countries studied. By ATC level 1 class, the highest PE was A (alimentary tract and metabolism) at 4.3 billion USD, and L (antineoplastic and immunomodulating agents) had the highest increase at 13.4%; in contrast, J (anti-infectives for systemic use) had the lowest increase in annual average PE at −0.2% in 2020 relative to 2011. Among the 17 OECD countries, Korea had the highest and the third-highest expenditures for ATC codes A and J, respectively. Conclusion: PE in Korea has continued to increase between 2011 and 2020, indicating the need for macroscopic management of PE. Our results on PE by ATC code may help health authorities in establishing future policies on PE.
참고문헌 (33)
- OECD, "Improving forecasting of pharmaceutical spending-insights from 23 OECD and EU countries. Analytic report" (2019), OECD Publishing
- "Global medicine spending and usage trends: outlook to 2025" (2021)[URL]
- "Health at a Glance 2021"[URL]
- "Global Spending and Demand for Medicines: Up or Down?"[URL]
- Mols F, "Financial toxicity and employment status in cancer survivors. A systematic literature review", Support Care Cancer, 28, pp.5693~5708 (2020)
- Economic papers 461: Cost-containment policies in public pharmaceutical spending in the EU, "European Commision", European Commision, ~, pp.European Economy. Economic papers 461 (2012)
- Dusetzina SB, "Prescription drug spending in fee-for-service medicare, 2008-2019", JAMA, 328, pp.1515~1522 (2022)
- "Stat" (2022)[URL]
- Korean Statistical Information Service(KOSIS), "Population census", KOSIS, ~ (2022)
- Health-care systems: lessons from the reform experience (December 10, 2003), "Docteur E", ~, pp.OECD Health Working Papers No. 9, OECD Economics Department Working Papers No. 374 (2023)
- Kim W, "The effects of cost containment and price policies on pharmaceutical expenditure in South Korea", Int J Health Policy Manag, 11, pp.2198~2207 (2021)
- "Plan to improve patient access to high-cost medicines for severe disease and to strengthen reimbursement management" (2022)[URL]
- "Anatomical Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) Index" (2021)[URL]
- "Purchasing Power Parity. What Is It, Theory, Calculations"[URL]
- Scholten GR, "Cost-control and medical specialist payment : the Dutch alternative", Int J Health Plann Manage, 13, pp.69~82 (1998)
- Cho DY, "The impact of expanding health insurance coverage for anti-cancer drugs on cancer survival in Korea", Cancer Med, 10, pp.4555~4563 (2021)
- Lee H, "Determinants of growth in prescription drug spending using 2010-2019 health insurance claims data", Front Pharmacol, 12, pp.681492~ (2021)
- Park D, "Determinants of growth in prescription drug spending : analysis of drug spending contribution using index", HIRA Res, 1, pp.208~220 (2021)
- "The statistics on reimburesed medicine use" (2021)[URL]
- "Health at a Glance 2015. Pharmaceutical spending trends and future challeges"[URL]
- Annadurai K, "Personalized medicine : a paradigm shift towards promising health care", J Pharm Bioallied Sci, 8, pp.77~78 (2016)
- Tebani A, "Omics-based strategies in precision medicine : toward a paradigm shift in inborn errors of metabolism investigations", Int J Mol Sci, 17, pp.1555~ (2016)
- Laviana AA, "Trends in the cost of cancer care : beyond drugs", J Clin Oncol, 38, pp.316~322 (2020)
- Leighl NB, "An Arm and a leg : The rising cost of cancer drugs and impact on access", Am Soc Clin Oncol Educ Book, 41, pp.1~12 (2021)
- "April, 2023 National Health Insurance Reimbursement Medicine List. Monthly"[URL]
- Chae J, "Changes in antibiotic consumption patterns after the implementation of the National Action Plan according to the Access, Watch, Reserve(AWaRe)classification system", Int J Infect Dis, 122, pp.345~351 (2022)
- "The prescription rate of antibiotics for common cold has been cut in half in 20 years. July 28 2022"[URL]
- Hobson CA, "Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect", Clin Microbiol Infect, 27, pp.1172~ (2021)
- Yoon Young Kyung, "Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults", Infection and Chemotherapy, 54(4), pp.812~853 (2022), 대한감염학회[DOI]
- Kim Chung-Jong, "Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship Programs", Infection and Chemotherapy, 54(4), pp.674~698 (2022), 대한감염학회[DOI]
- Cheong Hae Suk, "Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals", Infection and Chemotherapy, 54(4), pp.637~673 (2022), 대한감염학회[DOI]
- Kim Hyung-Sook, "Development of a Roadmap for the Antimicrobial Usage Monitoring System for Medical Institutions in Korea: a Delphi Study", Infection and Chemotherapy, 54(3), pp.483~492 (2022), 대한감염학회[DOI]
- Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]